Esteve Healthcare
↗Barcelona, Spain
Esteve Healthcare is a global specialty pharmaceutical company and contract development and manufacturing organization (CDMO) headquartered in Barcelona, Spain. Founded in 1929, the company has evolved from a family-owned pharmacy into an international leader in specialized medicine, focusing on high-unmet-need areas such as the central nervous system (CNS), oncology, and rare diseases. The company operates through two primary business units: a proprietary pharmaceutical division and a global CDMO division (Esteve Química).
In recent years, Esteve has undergone a significant strategic transformation, divesting its generics business to focus on proprietary specialty products and expanding its international footprint, particularly in the United States and Northern Europe. The company is recognized for its commitment to sustainability, having achieved B Corp certification in early 2026. With a robust manufacturing network spanning Europe, Asia, and the Americas, Esteve provides end-to-end services from preclinical development to commercial API production.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$700M-$800M
Founded:1929
Ownership:private
Status:operating
FUNDING
Stage:Private Equity
Total Raised:Undisclosed
Investors:Lubea (German private investment firm, 26% stake), Grupo Esteve Lifesciences (Majority shareholder)
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Gene therapy (AAV vectors), Biologicals
Active Trials:12
Trial Phases:Phase 1: 2 | Phase 2: 4 | Phase 3: 3 | Phase 4: 3
FDA Approvals:3
EMA Approvals:5
CORPORATE STRUCTURE
Parent Company:Grupo Esteve Lifesciences
Subsidiaries:Esteve Pharmaceuticals, S.A., Esteve Química, S.A. (CDMO), Riemser Pharma GmbH, Regis Technologies, Inc., HRA Pharma Rare Diseases
Key Partnerships:Teijin (Joint venture: Esteve Teijin Healthcare for respiratory therapy), Universitat Autònoma de Barcelona (Gene therapy R&D), Helsinn Group (Commercialization of Akynzeo and Aloxi), Eton Pharmaceuticals (Licensing for growth factor treatment)
COMPETITION
Position:Challenger
Competitors:Almirall, Grünenthal, Vertex Pharmaceuticals, Novartis, Merck & Co., Teva Pharmaceutical Industries
LEADERSHIP
Key Executives:
Staffan Schüberg - CEO
Albert Esteve - Chairman
José María Giménez - Chief Scientific & Medical Officer
Roser Gomila - CFO
Scientific Founders:Dr. Antoni Esteve i Subirana (Founder)
Board Members:Albert Esteve (Chairman), Jacques Tapiero, Catherine Moukheibir, Jane Griffiths, Staffan Schüberg, Wolfram von Braunschweig (Lubea representative)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Esteve Healthcare. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.